Nuvo Research Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Claude Cormier who wrote (11853)	1/12/2003 2:56:42 PM
From: Montana Wildhack	Read Replies (1) of 14101

Hi Claude, Rebecca spent a considerable amount of time discussing this at the AGM in October. As she explained it, this was a decision made by OXO that she did not appear to agree with; but, felt they had to go down the road with when considering the cost and time to make a change at that point. She expressed real dissatisfaction with the outfit that was hired by OXO to gather the data and refered to putting a full time Dimethaid employee there just to help nudge things along and help add what focus she could. There were a number of rumours floating around that this would be completed by December 31; but, when taking into account the record to date, I would not count myself as hopeful that this timeline would be achieved. However, we wouldn't know since at that point Dimethaid would have more work to do to be able to report on the results. If Rebecca is successful at launching in Canada on a timely basis and can close the remaining FDA issue some time this winter, I can see DMX would be in a good position to take in some comparatively serious money to fund the next steps in both this and fungoff. At the moment, I'm pretty sure the tactic at this time is to get through these low stock prices without major financing and tightening the belt until it hurts. It's irrefutable that funds have been received and I suspect from a variety of situations. If HC comes through quite readily (which is the word), then full approval and a quick launch date should add material value to the stock price. I see something north of $4 as quite reasonable on that news. I do see getting the WF10 results in 2003. More than when we finally get away from those slugs handling the data gathering - I will want to see signs that REK learned from her FDA experiences and moves to add value from this investment. This patent expires in 2017 and while WF10 has kept under the radar screen - I believe good results from the phase III (no matter how clean) will add a potential to this side of things that will become important to our investment here with regard to valuation. Wolf

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next